South America Bladder Cancer Therapeutics and Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 3.00 % |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
South America Bladder Cancer Therapeutics and Diagnostics Market Analysis
The South America Bladder Cancer Therapeutics and Diagnostics Market is projected to record a CAGR of 3.0% over the forecast period.
COVID-19 had a significant impact on the growth of the studied market. According to an article published in Elsevier in April 2021, it was observed that the average number of cancer diagnoses had dropped considerably in all Brazilian regions during the pandemic period, ranging from 24.3% in the North to 42.7% in the Northeast. Also, as per the same source, about a 66% reduction in the number of bladder diagnoses was reported in Brazil during the pandemic. However, the released restrictions and resumed diagnostics and treatment services have increased patient visits to the hospitals, which are expected to fuel the market growth over the forecast period.
Factors such as increasing awareness about bladder diseases, increasing healthcare expenditure, innovations in drug development, and availability of therapies are all expected to boost market growth over the forecast period.
The increasing prevalence of bladder cancer is the key factor driving the demand for effective therapeutics and novel diagnostics systems in the region. This is anticipated to fuel market growth. For instance, according to the 2023 statistics published by the Global Cancer Observatory, an estimated 4,176 new bladder cancer cases are expected to be diagnosed in Argentina in 2025, as compared to 3,785 cases during the pandemic (2020). In addition, as per the same source, about 2,403 and 1,823 new bladder cancer cases are expected to be diagnosed in Colombia and Chile, respectively, in 2025.
Additionally, the growing government and organizations' initiatives in launching awareness programs and campaigns regarding bladder cancer, its related therapeutics, and diagnostic methods are expected to increase the demand for treatment procedures. This is expected to augment the market growth in the region over the forecast period.
Furthermore, the rising company focus on adopting various strategies, such as product launches and mergers and acquisitions, increases the development and availability of novel products, which in turn also contributes to market growth. For instance, in August 2021, Photocure ASA, the Bladder Cancer Company, received the market authorization, for Hexvix, from Instituto de Salud Pública de in Chile.
Therefore, owing to the aforementioned factors, the studied market is anticipated to grow over the forecast period. However, the rise in the number of patent expirations and the asymptomatic nature of the disease is likely to impede the growth of the bladder cancer therapeutics and diagnostics market in South America over the forecast period.
South America Bladder Cancer Therapeutics and Diagnostics Market Trends
Cystoscopy Segment Expects to Register a Significant Growth Over the Forecast Period
Cystoscopy is a procedure used to observe the interiors of the bladder and urethra using a telescope. A cystoscope is a specialized endoscope that is inserted through the urethra into the bladder to allow direct visual inspection of the urothelium. Cystoscopy is cost-effective. The segment is driven by rising in the adoption of cystoscopy, the rising prevalence of bladder cancer, and product launches by the key market players.
According to an article published in BMC, in February 2021, it has been observed that fluorescent cystoscopy using 5-aminolevulinic acid (ALA) or its hexyl ester, hexaminolevulinate improves tumor detection rate and recurrence-free survival (RFS) compared to white-light cystoscopy alone, in bladder cancer treatment. This is expected to increase the adoption of cystoscopy in the diagnosis of bladder cancer which in turn is anticipated to augment the segment's growth over the forecast period.
Therefore, owing to the aforementioned factors, such as the high adoption of cystoscopy, the studied market is expected to grow over the forecast period.
Brazil is Expected to Have the Significant Market Share Over the Forecast Period
Brazil is expected to witness a significant share in the bladder cancer therapeutics and diagnostics market over the forecast period. The factors propelling the market growth are the increasing burden of various types of bladder cancer and rising research studies.
According to an article published in the Journal of Epidemiology and Global Health, in September 2022, it has been observed that bladder cancer is the seventh most prevalent cancer in men and the sixteenth most prevalent cancer in women, in Brazil. Thus, the high burden of bladder cancer among the Brazillian population raises the demand for effective therapeutics and diagnostics devices which in turn is anticipated to fuel the market growth over the forecast period.
Additionally, the growing company activities in developing various diagnostic tests and products to effectively diagnose bladder cancer among the population is expected to fuel the market growth over the forecast period. For instance, in January 2023, Hoffmann-La Roche is conducting a Phase III clinical study to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with placebo in participants with muscle-invasive bladder cancer who are ctDNA positive and are at high risk for recurrence following cystectomy, in Brazil. Also, in April 2021, Solve Biotechnology researchers, a Brazillian start-up company, are developing a rapid test to diagnose bladder cancer to reduce the number of invasive tests to which patients are submitted from the discovery of cancer to the end of treatment.
Therefore, owing to the above-mentioned factors such as the high burden of bladder cancer and increasing company activities, the studied market is expected to grow in Brazil over the forecast period.
South America Bladder Cancer Therapeutics and Diagnostics Industry Overview
The South American Bladder Cancer Market is moderately competitive and majorly dominated by a few players. With the rising technology and focus of various companies on drug discovery, it has been believed that several new companies will be entering the market in the coming future and are expected to hold a significant market share. Some of the key companies in the market are Pfizer Inc., Astra Zeneca PLC, Bristol Myers Squibb, Johnson and Johnson Inc., and Merck & Co. Inc., among others.
South America Bladder Cancer Therapeutics and Diagnostics Market Leaders
-
Pfizer Inc.
-
Johnson and Johnson
-
AstraZeneca
-
Bristol-Myers Squibb Company
-
Merck & Co., Inc.
*Disclaimer: Major Players sorted in no particular order
South America Bladder Cancer Therapeutics and Diagnostics Market News
- Feb 2023: Janssen Research & Development LLC is conducting a Phase III clinical study to evaluate the safety and efficacy of TAR-200 in combination with cetrelimab or TAR-200 alone versus intravesical bacillus Calmette-guérin (BCG) in participants with BCG-naïve high-risk non-muscle invasive bladder cancer, in Brazil.
- Feb 2023: AstraZeneca is conducting a Phase III clinical study to determine the safety and efficacy of a triplet combination of durvalumab, tremelimumab, and enfortumab vedotin to the current standard of care in patients with muscle-invasive bladder cancer.
South America Bladder Cancer Therapeutics & Diagnostics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions & Market Defination
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness about Bladder Diseases, and Available Therapies
4.2.2 Increasing Healthcare Expenditure
4.2.3 Innovations in Drug Development
4.3 Market Restraints
4.3.1 Rise in the number of Patent Expirations
4.3.2 Asymptomatic Nature of the Disease
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Cancer Type
5.1.1 Transitional Cell Bladder Cancer
5.1.2 Superficial Bladder Cancer
5.1.3 Invasive Bladder Cancer
5.1.4 Squamous Cell Bladder Cancer
5.1.5 Other Rare Types
5.2 By Therapeutics
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Radiation Therapy
5.2.4 Surgery
5.3 By Diagnostics
5.3.1 Cytoscopy
5.3.2 Biopsy
5.3.3 Urinalysis
5.3.4 Urine Ctyology
5.3.5 Bladder Ultrasound
5.4 By Geography
5.4.1 South America
5.4.1.1 Brazil
5.4.1.2 Argentina
5.4.1.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Novartis AG
6.1.2 Pfizer Inc.
6.1.3 GlaxoSmithKline Plc.
6.1.4 Sanofi S.A.
6.1.5 Eli Lilly and Co.
6.1.6 Astra Zeneca Plc.
6.1.7 Bristol Myers Squibb
6.1.8 Hoffmann-La Roche AG
6.1.9 Johnson & Johnson (Janssen Pharmaceutical)
6.1.10 Bracco
6.1.11 Ono Pharmaceutical Co. Ltd
6.1.12 Nektar Therapeutics
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
South America Bladder Cancer Therapeutics and Diagnostics Industry Segmentation
As per the scope of the report, bladder cancer is a tumor that starts in the cells of the bladder. Bladder cancer is the rapid, uncontrolled growth of abnormal cells in the urinary bladder lining with epithelial cells. These cancerous cells may even spread through the lining into the muscular wall of the bladder. Several therapies have been developed to treat bladder cancers, which, in turn, build a high demand for the bladder cancer therapeutics market.
The South American Bladder Cancer Therapeutics and Diagnostics Market is Segmented by Cancer Type (Transitional Cell Bladder Cancer, Superficial Bladder Cancer, Invasive Bladder Cancer, Squamous Cell Bladder Cancer, and Other Rare Types), Therapeutics (Chemotherapy, Immunotherapy, Radiation Therapy, and Surgery) Diagnostics (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, and Bladder Ultrasound) and Geography. The report offers the value (in USD million) for the above segments.
| By Cancer Type | |
| Transitional Cell Bladder Cancer | |
| Superficial Bladder Cancer | |
| Invasive Bladder Cancer | |
| Squamous Cell Bladder Cancer | |
| Other Rare Types |
| By Therapeutics | |
| Chemotherapy | |
| Immunotherapy | |
| Radiation Therapy | |
| Surgery |
| By Diagnostics | |
| Cytoscopy | |
| Biopsy | |
| Urinalysis | |
| Urine Ctyology | |
| Bladder Ultrasound |
| By Geography | |||||
|
South America Bladder Cancer Therapeutics & Diagnostics Market Research FAQs
What is the current South America Bladder Cancer Therapeutics and Diagnostics Market size?
The South America Bladder Cancer Therapeutics and Diagnostics Market is projected to register a CAGR of 3% during the forecast period (2024-2029)
Who are the key players in South America Bladder Cancer Therapeutics and Diagnostics Market?
Pfizer Inc., Johnson and Johnson, AstraZeneca, Bristol-Myers Squibb Company and Merck & Co., Inc. are the major companies operating in the South America Bladder Cancer Therapeutics and Diagnostics Market.
What years does this South America Bladder Cancer Therapeutics and Diagnostics Market cover?
The report covers the South America Bladder Cancer Therapeutics and Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the South America Bladder Cancer Therapeutics and Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
South America Bladder Cancer Therapeutics and Diagnostics Industry Report
Statistics for the 2024 South America Bladder Cancer Therapeutics and Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. South America Bladder Cancer Therapeutics and Diagnostics analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
